Shri Ahimsa Naturals Limited is a global leader in circular innovation, specializing in the extraction of high-value compounds from natural waste and underutilized by-products. With over **35 years** of industry expertise and **20+ years** of dedicated R&D in caffeine purification, the company is the **largest Natural Caffeine manufacturer in India** and a dominant global player. The company operates a "Waste-to-Value" model, transforming tea waste, coffee residues, and crude caffeine into premium ingredients for the Food & Beverage, Nutraceutical, Cosmetic, and Pharmaceutical industries. --- ### **Proprietary Technology & Product Ecosystem** The company utilizes in-house developed solvent extraction technology to process crude caffeine sourced from decaffeination plants in regions such as **Vietnam and Mexico**. * **Caffeine Anhydrous Natural:** A food-grade natural stimulant positioned as a premium alternative to synthetic caffeine. * **Green Coffee Bean Extract (GCE):** A high-value byproduct of the caffeine extraction process, rich in **chlorogenic acid** and **antioxidants**, primarily used for weight management. * **Herbal Extracts:** A diversified portfolio including **Senna Leaf, Ashwagandha, Turmeric, Curcumin, and Garcinia**. While currently outsourced, production is being internalized through new facilities. * **Crude Caffeine Production:** Since **2022**, the company has backward-integrated to manufacture crude caffeine directly from tea and coffee sludge/wax. #### **Comparative Market Advantage: Natural vs. Synthetic** | Feature | Natural Caffeine (Shri Ahimsa) | Synthetic Caffeine | | :--- | :--- | :--- | | **Source** | Tea & Coffee waste (Circular) | Chemically synthesized from **Urea** | | **Pricing** | **3x** premium over Synthetic | Commodity pricing | | **Market Share** | **10%** (High-growth niche) | **90%** (Mass market) | | **Consumer Impact** | Gradual release; no "jitters" | Sudden energy spikes and "crashes" | | **Cost Position** | **Global Cost Leader** | High-volume competition | --- ### **Manufacturing Infrastructure & Massive Capacity Expansion** The company is currently undergoing a transformative scaling phase to transition from a specialized extractor to a diversified healthcare and herbal player. | Facility Location | Product Segment | Current Capacity | Upcoming/New Capacity | | :--- | :--- | :--- | :--- | | **Bagru, Jaipur (RIICO)** | Caffeine Anhydrous | **270 MTPA** | - | | | Green Coffee Bean Extract | **200 MTPA** | - | | **Sawarda, Jaipur (SAHPL)**| Caffeine Anhydrous | - | **700 MTPA** | | | Green Coffee Bean Extract | - | **300 MTPA** | | | Crude Caffeine | - | **63 MTPA** | | | Herbal Extracts | Outsourced | **In-house (Fungible)** | **The Sawarda Greenfield Project:** Executed through the wholly-owned subsidiary **Shri Ahimsa Healthcare Private Limited (SAHPL)**, this **₹61 Crore** investment is funded via **₹35 Crore** from IPO proceeds and internal accruals. As of **Q3FY26**, **₹21.16 Crore** has already been deployed into the facility. --- ### **Financial Performance & Capital Structure** Shri Ahimsa Naturals listed on the **NSE Emerge** platform on **April 2, 2025**, following an IPO that was subscribed **62.71 times**, reflecting strong investor confidence. * **Revenue Growth:** Consolidated revenue reached **₹95.81 Crore** in **FY 2024-25**, a **22.86%** increase year-on-year. * **Profitability:** Maintained a robust **EBITDA Margin of ~34%** and a **Net Profit (PAT) of ₹21.90 Crore**. * **Export Dominance:** **91%** of revenue (**₹86.8 Crore**) is derived from exports to **14+ countries**, including the **USA, Germany, UK, Italy, Japan, and South Korea**. * **Solvency:** The company achieved **Net Debt-Free** status in **FY 2024-25** with a **Return on Capital Employed (ROCE) of ~26%**. #### **Recent Strategic Funding (Late 2025)** To fuel further expansion, the Board approved a dual-track fundraising effort: 1. **Preferential Allotment:** Issuance of **1,00,800 shares** at **₹227 per share** (raising **₹2.28 Crore**). 2. **Convertible Warrants:** Issuance of **13,34,400 warrants** to raise **₹30.29 Crore** over 18 months. * **Allocation:** **85%** of these funds are earmarked for **Business Expansion, R&D, and Working Capital**. --- ### **Strategic Growth Pillars & Global Outlook** * **Premiumization Trend:** The global Caffeine Anhydrous market is projected to reach **$881.5 Million by 2030** (**6.88% CAGR**), driven by the shift toward "natural" labeling in developed economies. * **Supply Chain Resilience:** The company is broadening its supplier base for crude caffeine to reduce dependency and has noted that caffeine is currently **exempted from US tariffs**, protecting its largest export market. * **Quality Benchmarking:** Holds **FSSC 22000 approval**, essential for securing long-term contracts with global energy drink and pharmaceutical giants. * **Target Targets:** Management aims for **15%–25% annual revenue growth** and entry into at least **two new product segments** in the medium term. --- ### **Risk Factors & Contingencies** Investors should monitor the following operational and regulatory nuances: * **Capital Allocation Discipline:** A **material deviation** of **₹2.50 Crore** was reported in **Q2FY26** regarding the use of fixed deposit proceeds. While rectified in **Q3FY26**, it highlights the need for oversight on fund utilization. * **Audit Qualifications:** Auditors issued **adverse remarks** under **CARO 2020** for both the parent and subsidiary (Clauses including **7(a)** and **9(b/d)**), relating to statutory dues or reporting consistencies. * **Asset Execution Delays:** A **₹21 Lakh** advance for **3.51 Bigha** of agricultural land in Jaipur has remained outstanding since **January 2023** without the execution of a purchase agreement. * **Pending Insurance Claim:** A claim of **₹58.49 Lakhs** for fire damage sustained in **FY 2023-24** remains pending with United India Insurance. * **Customer Concentration:** While improving, one major customer still accounts for approximately **35%** of total revenue.